Stock

Novartis CEO ‘very confident’ on sales target, doesn’t fear patent cliff – newspaper

ZURICH (Reuters) – Novartis (SIX:NOVN) expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant having nothing to fear from the end of patent protection on some drugs.

“I am very confident that we will achieve average growth of at least 5% per year until 2028,” Narasimhan told Swiss newspaper Finanz und Wirtschaft.

This would be made possible by eight or nine drugs with multi-billion dollar sales, he told the newspaper, although a big challenge will be maintaining the pipeline of new medications.

Narasimhan said he was confident the company would reach its growth target despite the imminent expiry of patents on some medications including Entresto used to treat heart failure.

“We also expect sales and profit growth for 2025. We will announce a specific forecast in January,” said Narasimhan, who has led Novartis since 2018.

“In the past, the expiry of major patents in our industry has often led to declining sales, but this is not to be feared at Novartis.”

The company will not, however, increase its core operating profit margin much beyond the current level of 40.1%, Narasimhan said.

“I consider a margin in the low 40% range to be sufficient – higher margins are generally not rewarded in the pharmaceutical industry as they come at the expense of investments in research, development and sales growth,” he said.

Novartis will also consider acquisitions, with a focus on bolt-on deals worth less than $1 billion.

“Of course, we will continue to look for deals of up to $10 billion or more,” Narasimhan said. “However, our analysis shows that the track record of such deals in the sector has historically been rather poor.”

This post appeared first on investing.com

You May Also Like

Editor's Pick

Sen. JD Vance (R-Ohio) and Minnesota Gov. Tim Walz (D) will face off Tuesday night at a CBS News vice-presidential debate in New York....

Latest News

A North Korean defector who escaped to the South more than a decade ago was detained after attempting to cross back into North Korea...

Economy

A U.N. human rights group confirmed Hamas’ leader in Lebanon, who was recently killed by Israeli strikes, was their employee.  Fateh Sherif was killed...

Investing

Astron (ASX:ATR) and Energy Fuels (TSX:EFR,NYSEAMERICAN:UUUU) have completed the establishment of a joint venture to advance the Australia-based Donald rare earths and mineral sands...

Disclaimer: balanceandcharge.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 balanceandcharge.com

Exit mobile version